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Coronary Computed Tomography 
Angiography Compared With Single Photon 
Emission Computed Tomography Myocardial 
Perfusion Imaging as a Guide to Optimal 
Medical Therapy in Patients Presenting With 
Stable Angina: The RESCUE Trial
Arthur E. Stillman , MD, PhD; Constantine Gatsonis, PhD; Joao A.C. Lima , MD; Tao Liu, PhD;  
Bradley S. Snyder, MS; Jean Cormack, PhD; Vinay Malholtra, MD; Mitchell D. Schnall, MD, PhD;  
James E. Udelson, MD; Udo Hoffmann, MD, MPH; Pamela K. Woodard , MD; the RESCUE investigators*
BACKGROUND: The RESCUE (Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive 
Examinations) trial was a randomized, controlled, multicenter, comparative efficacy outcomes trial designed to assess whether 
initial testing with coronary computed tomographic angiography (CCTA) is noninferior to single photon emission computed 
tomography (SPECT) myocardial perfusion imaging in directing patients with stable angina to optimal medical therapy alone 
or optimal medical therapy with revascularization.
METHODS AND RESULTS: The end point was first major adverse cardiovascular event (MACE) (cardiac death or myocardial in-
farction), or revascularization. Noninferiority margin for CCTA was set a priori as a hazard ratio (HR) of 1.3 (95% CI=0, 1.605). 
One thousand fifty participants from 44 sites were randomized to CCTA (n=518) or SPECT (n=532). Mean follow-up time was 
16.2 (SD 7.9) months. There were no cardiac-related deaths. In patients with a negative CCTA there was 1 acute myocardial 
infarction; in patients with a negative SPECT examination there were 2 acute myocardial infarctions; and for positive CCTA 
and SPECT, 1 acute myocardial infarction each. Participants in the CCTA arm had a similar rate of MACE or revascularization 
compared with those in the SPECT myocardial perfusion imaging arm, (HR, 1.03; 95% CI=0.61-1.75) (P=0.19). CCTA segment 
involvement by a stenosis of ≥50% diameter was a better predictor of MACE and revascularization at 1 year (P=0.02) than the 
percent reversible defect size by SPECT myocardial perfusion imaging. Four (1.2%) patients with negative CCTA compared 
with 14 (3.2%) with negative SPECT had MACE or revascularization (P=0.03).
CONCLUSIONS: There was no difference in outcomes of patients who had stable angina and who underwent CCTA in compari-
son to SPECT as the first imaging test directing them to optimal medical therapy alone or with revascularization. CCTA was a 
better predictor of MACE and revascularization.
REGISTRATION INFORMATION: URL: https://www.clini caltr ials.gov/. Identifier: NCT01262625.
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Ischemic heart disease is the main cause of morbid-ity and mortality worldwide, and will likely remain so for at least the next decade.1,2 The goal in treating 
patients with symptoms suggestive of stable ischemia 
is to diagnose them in the most efficient way possible 
in order to reduce their risk of death and myocardial 
infarction.2,3 All patients with coronary artery disease 
(CAD) with or without revascularization should be 
treated with guideline-driven optimal medical therapy 
(OMT).3,4 A number of trials,5–7 including the most recent 
ISCHEMIA (International Study of Comparative Health 
Effectiveness With Medical and Invasive Approaches) 
trial,8 showed no evidence to suggest that an initial 
invasive strategy, as compared with an initial conser-
vative strategy, reduced the risk of ischemic cardio-
vascular events or death. Moreover, elective invasive 
coronary angiography (ICA) in chronic stable angina 
has been shown to be of low yield in many patients,9 
and has the potential to directly increase the number 
of unnecessary invasive catheter-based and surgical 
revascularization procedures.10 Myocardial perfusion 
by single photon emission computed tomography 
myocardial perfusion imaging (SPECT-MPI) has been 
the main noninvasive strategy used as a gatekeeper 
to ICA and percutaneous coronary intervention, but its 
effectiveness is low as an index of obstructive disease 
by ICA.11
Coronary computed tomographic angiography 
(CCTA), an anatomic imaging modality, is a potential 
alternative to SPECT-MPI as the first line of testing in 
patients with stable chest pain and suspected CAD, 
and is now the recommended first line of testing in the 
United Kingdom12,13 and in developing countries, where 
the modality of CT is easily accessible and where mor-
bidity and mortality caused by CAD is on the rise.12–15
In this trial we assess, in a head-to-head com-
parison, CCTA- and SPECT-MPI-driven imaging 
algorithms.
METHODS
Requests to access the data set may be submitted 
to the American College of Radiology (ACR) Center 
for Research and Innovation (CRI) via https://dart.acr.
org.
Study Design
The RESCUE (Randomized Evaluation of Patients 
with Stable Angina Comparing Utilization of 
Noninvasive Examinations) Trial is a phase III, rand-
omized, controlled, multicenter, comparative efficacy 
study, designed to compare 2 diagnostic imaging/
treatment paradigms that use CCTA or SPECT-MPI 
for assisting in the diagnosis of ischemic heart dis-
ease in patients with stable angina symptoms, and 
guiding subsequent treatment (Figure 1A). Stable an-
gina was defined as having Class I or II angina by the 
Canadian Cardiovascular Society.16 The study design 
was previously reported, to include the Consolidated 
CLINICAL PERSPECTIVE
What Is New?
• This randomized, controlled, multicenter, com-
parative efficacy outcomes trial tested whether 
initial testing with coronary computed tomo-
graphic angiography is noninferior to single pho-
ton emission computed tomography myocardial 
perfusion imaging in directing patients with sta-
ble angina to optimal medical therapy alone or 
optimal medical therapy with revascularization.
• Participants in the coronary computed tomo-
graphic angiography arm had similar rate of 
major adverse cardiovascular events or revas-
cularization compared with those in the single 
photon emission computed tomography myo-
cardial perfusion imaging arm.
What Are the Clinical Implications?
• This trial provides further evidence in support 
of a coronary computed tomographic angiogra-
phy first strategy for the diagnosis and manage-
ment of patents presenting with symptoms of 
stable angina.
Nonstandard Abbreviations and Acronyms
OMT optimal medical therapy
ICA invasive coronary angiography
Figure 1. RESCUE (Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Noninvasive 
Examinations) Schema and Consolidated Standards of Reporting Trials (CONSORT) diagram.
A, Patients with symptoms of stable angina were randomized to receive either CCTA or SPECT-MPI. Diagnostic ICA was performed 
in select patients according to the schema. All were followed for MACE/revascularization. B, CONSORT diagram. There were 1050 
patients who were randomized (518 CCTA, 532 SPECT-MPI). CCTA was performed in 473 and SPECT-MPI was performed in 464. 
There were 401 patients for CCTA and 378 patients for SPECT-MPI for evaluation of the secondary end point. CAD indicates coronary 
artery disease; CCS, Canadian Cardiovascular Society; CCTA, coronary computed tomographic angiography; ICA, invasive coronary 
angiography; LMD, Left main disease; MACE, major cardiovascular events; OMT, optimal medical therapy; and SPECT-MPI, single 
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Standards of Reporting Trials flow diagram, which 
we re-present in Figure 1B.17,18 The study protocol 
was approved by the Institutional Review Boards at 
each study site, or through a commercial Institutional 
Review Board (Advarra Schulman). All patients pro-
vided written, informed consent. In the CCTA arm, 
patients without left main disease were treated with 
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reversible defect were directed to ICA, and patients 
without left main disease by ICA were treated with 
OMT. The Data Coordinating Center generated the 
random allocation sequence and assigned par-
ticipants to the 2 study arms in equal proportions. 
Blocked randomization was used, stratified by sex 
and participating institution. Randomization was 
done at the time of study enrollment. All investiga-
tors and site coordinators involved in the trial were 
blinded to randomization until after patient recruit-
ment and assignment to the study arm (initial imaging 
test). The site coordinators enrolled the participants.
The RESCUE (Randomized Evaluation of Patients 
with Stable Angina Comparing Utilization of Noninvasive 
Examinations) trial, funded by the Agency for Healthcare 
Research and Quality and the American College 
of Radiology Imaging Network Fund for Imaging 
Innovation, began in 2011, and was completed in 2014. 
Adherence to OMT was determined by patient follow-up. 
Participants with positive cardiac-related findings on 
their CCTA or SPECT/MPI were contacted at a minimum 
of 4 time points (at 2 weeks and 2, 6, and 12 months). 
Participants with negative findings on CCTA or SPECT 
MPI were contacted at a minimum of 2 time points (6 and 
12 months). Participants were then contacted every 6 
months until the conclusion of the trial.18 The main fund-
ing mechanism was through the American Recovery 
and Reinvestment Act. Unfortunately, this limited the 
time possible for patient recruitment and follow-up. As 
a result, the recruitment goal was not achieved which 
limits the statistical power for data analysis.
Statistical Analysis
The primary aim of the study was to compare the 
time-dependent rates of the composite primary end 
point (major adverse cardiovascular event [MACE], 
comprising cardiac-related death or acute myocar-
dial infarctions [AMI], and revascularization) across 
the 2 arms of the trial. Time to the primary end 
point was measured from randomization to CCTA or 
SPECT-MPI to the first occurrence of any of the com-
ponent events. The primary analysis was conducted 
from an intent-to-treat perspective, with time to event 
compared between the CCTA and SPECT-MPI arms 
using Kaplan-Meier curves with log-rank test. Cox 
regression models were used to estimate the hazard 
ratio to compare against the predefined noninferior-
ity margin. The study was designed to achieve suf-
ficient power with 4300 subjects in order to test the 
noninferiority of CCTA compared with SPECT-MPI to 
guide medical therapy, where the noninferiority mar-
gin was defined as a hazard ratio of 1.3 (95% CI=0, 
1.605). The hazard ratio 1.3 margin was chosen in 
that, given the projected sample size, it would pro-
vide 85% power.18
Secondary aims of the trial were (1) to evaluate the 
ability of available prognostic indices to predict the 
composite outcome status (MACE and revascular-
ization) at 1 year, and (2) to develop a new predictive 
index of composite outcome status at 1 year using 
RESCUE data. For these secondary analyses, pa-
tients with <1-year follow-up (defined as <335 days) 
were excluded from analysis, as were ineligible 
patients and patients without the respective ran-
domized scan or with an uninterpretable scan. The 
ability of the Modified Duke Score from CCTA,19 and 
percent reversible defect size on SPECT to predict 
1-year composite outcome status were assessed 
by receiver operating characteristic analysis, with 
comparison by arm performed using the method of 
DeLong.20
In developing a new predictive index, the 
Modified Duke Score was replaced with a pre-
dictive model based upon the raw CCTA steno-
sis data. The American Heart Association (AHA) 
16-segments were graded as being normal (0%), 
very mild (1%–29%), mild (30%–49%), moderate 
(50%–69%), or severe (≥70%) stenosis. Because 
of the relatively few MACE events, these were 
grouped to < 30%, 30%–49%, and ≥50% for sub-
sequent analysis. A new index was derived using 
the individual AHA 16-segment stenosis scores. 
The association between each coronary artery 
segment and composite outcome status at 1 year 
was assessed using the exact χ2 test (for cate-
gorical predictors), the nonparametric Wilcoxon 
rank sum test (for continuous predictors), and 
by the C-statistic from univariate logistic regres-
sion. Segment selection was performed using the 
grouped least absolute selection and shrinkage 
operator method21 with tuning parameter identi-
fied using 5-fold cross-validation in order to limit 
overfitting. Selected segments were then com-
bined into an ordinary multivariate logistic regres-
sion model, with predictive ability of the new index 
final model summarized using the C-statistic.
A P-value threshold of 0.05 was used to declare 
statistical significance. Statistical analyses were per-
formed using SAS 9.4 (SAS Institute) or R software 
(version 3.3.1; R project, http://www.r-proje ct.org).
RESULTS
Our study was designed to enroll and randomize 4300 
participants to the 2 study arms, but given the difficul-
ties of recruiting enough patients to fulfill the stringent 
entry criteria, as well as time constraints for funding 
(American Recovery and Reinvestment Act award, 
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Between May 2011 and April 2013, 1050 partici-
pants from 44 sites were enrolled and randomized in 
a 1:1 ratio to either CCTA or SPECT-MPI. Of the 1050 
participants, 3 were placed off-study, because of a 
duplicate registration (n=1), site Institutional Review 
Boards closure (n=1), and lack of informed consent 
(n=1). Demographics and CAD risk factors of the re-
maining 1047 participants are shown in Table  S1. 
Details of the participant flow through the trial are il-
lustrated in the Consolidated Standards of Reporting 
Trials diagram shown in Figure 1B.
Among the 1047 eligible participants, 110 (10.5%) 
participants did not have the randomized scan for 
reasons shown in Table S2. We continued to follow 
these 110 participants according to the study pro-
tocol. Since an intention-to-treat analysis was per-
formed, these 110 participants were included in the 
analysis of the primary aim. Mean follow-up time 
for all patients in the trial was 16.2 (SD 7.9) months. 
Imaging status with types of events is shown in 
Table S3. There were no cardiac-related deaths ob-
served in the study. There was 1 AMI for patients 
with negative CCTA, and 2 AMI for patients with a 
negative SPECT examination. There was 1 AMI each 
for patients with positive CCTA and SPECT examina-
tions. Among patients with negative CCTA examina-
tions, 4/345 (1.2%) had MACE or revascularization, 
whereas 14/436 (3.2%) patients with negative SPECT 
examinations had MACE or revascularization (log-
rank P=0.03). A total of 25/122 (20.5%) patients 
with positive CCTA had MACE or revascularization, 
whereas 8/23 (34.8%) patients with positive SPECT 
had MACE or revascularization (log rank P=0.24). 
There were 169 (32.8%) patients in the CCTA arm 
who had incidental findings, 59 of whom required 
follow-up imaging. In the SPECT MPI arm there were 
only 9 (1.7%) patients who had incidental findings, 2 
of whom required follow-up imaging.
Participants in the CCTA arm had a similar rate of 
experiencing the primary end point compared with 
those in the SPECT-MPI arm, with a hazard ratio esti-
mate of 1.03 (95% CI, 0.61–1.75). (P=0.19).
Imaging-associated adverse events were uncom-
mon in the trial (Table S4), with only 1 adverse event 
with an attribution of probable or definite in the CCTA 
arm that was judged to be moderate or greater in 
severity. There were no reported adverse events with 
attribution of probable or definite in the SPECT arm. 
In the trial overall, there were 10 reported deaths, of 
which none were determined to be cardiac (7 ma-
lignancy, 1 stroke, 1 cocaine drug overdose, and 1 
pulmonary end-stage chronic obstructive pulmonary 
disease).
Of the 145 patients with positive cardiac-related 
findings on their CCTA or SPECT/MPI, 128 patients 
could be contacted at 6 months, 118 at 12 months, 88 
at 18 months, and 47 at 24 months. Of the 781 patients 
with negative findings on CCTA or SPECT MPI, 654 
could be contacted at 6 months, 618 at 12 months, 
391 at 18 months, and 253 at 24 months. Adherence 
to OMT in patients with a positive examination, includ-
ing adherence to medical therapy (antihypertensives, 
medication for diabetes mellitus, and blood thinners) 
and nonsmoking was described by 44 (34.4%) of the 
128 patients who could be contacted at 6  months. 
Information regarding adherence to OMT is provided 
in Table S5.
A total of 401 patients were analyzed for CCTA and 
a total of 378 patients were analyzed for SPECT for 
purposes of the secondary end points. Relevant ex-
clusions are shown in Figure 1B. The derived Modified 
Duke Scores are shown in Table S6. The ability of the 
Modified Duke Score and percent reversible defect 
size on SPECT-MPI to predict composite outcome 
status (MACE and revascularization) at 1 year was as-
sessed by receiver operating characteristic analysis 
(Figure 2). While the Modified Duke Score had a higher 
area under the curve (area under the curve=0.87, 
95% CI, 0.81–0.94) than the percent reversible defect 
size (area under the curve=0.73, 95% CI, 0.59–0.88), 
this difference did not achieve statistical significance 
(P=0.08), likely because of the relatively few MACE and 
revascularization events.
In addition to assessing the prognostic ability of the 
Modified Duke Score on CCTA and percent reversible 
defect size on SPECT-MPI, a secondary aim for the trial 
was to develop a new index from the RESCUE data 
for prediction of composite outcome status at 1 year. 
The results from univariate logistic regression models 
assessing the predictive ability of each of the individ-
ual AHA 16-arterial segments are shown in Table S7. 
The C-statistic corresponds to the receiver operating 
characteristic area under the curve using the predicted 
values from the univariate regression model and gives 
a measure of strength of each predictor. The proximal 
and mid-left anterior descending artery segments ex-
hibited the largest C-statistics and were the only arte-
rial segments selected by the least absolute selection 
and shrinkage operator. The new CCTA model using 
only these 2 segments resulted in significantly better 
discriminatory ability for the composite outcome than 
the SPECT percent reversible defect size (P=0.02, 
Figure 3).
DISCUSSION
In the RESCUE trial, there was no difference in out-
comes of patients who had stable angina and who 
underwent CCTA in comparison to SPECT as the first 
imaging test directing them to OMT alone or with re-




 http://ahajournals.org by on A
ugust 10, 2021
J Am Heart Assoc. 2020;9:e017993. DOI: 10.1161/JAHA.120.017993 6
Stillman et al The RESCUE Trial
and revascularization. These findings are consistent 
with the findings of the recently published ISCHEMIA 
trial,8 which showed no evidence that an initial inva-
sive strategy, as compared with an initial conservative 
strategy, reduced the risk of ischemic cardiovascular 
events. In the ISCHEMIA trial, patients with an unpro-
tected left main stenosis of at least 50% diameter as 
determined by CCTA were excluded.8 RESCUE also 
excluded patients with left main disease as determined 
by either CCTA or ICA.
Thus, ISCHEMIA showed and RESCUE suggests 
that CCTA can be effectively used to direct patients 
to either revascularization (patients with left main dis-
ease) and OMT, or OMT alone. Under the ISCHEMIA/
RESCUE paradigm, CT fractional flow reserve would be 
required only in the assessment of left main disease. 
However, the accuracy of computational fluid dynamics 
methods to estimate fractional flow reserve by CCTA 
makes the case for use of CCTA more compelling.22,23
Like RESCUE, the PROMISE (Prospective 
Multicenter Imaging Study for Evaluation of Chest Pain) 
trial14 showed more frequent revascularization in pa-
tients who underwent CCTA in comparison to SPECT, 
and there was also a trend towards increased revas-
cularization for CCTA compared with standard care in 
the SCOT-HEART (Scottish Computed Tomography 
of the Heart) trial,24 although it did not reach statistical 
significance. While one may wonder whether these re-
vascularizations benefited the patient, fewer AMI and 
coronary heart disease deaths were found in the CCTA 
arm of SCOT-HEART, suggesting that CCTA was bet-
ter at identifying patients who ultimately benefitted from 
revascularization. In RESCUE, CCTA was a better pre-
dictor of MACE and revascularization. Previous trials 
Figure 2. Receiver operating characteristic curves show a trend towards improved prediction of 
the composite end point of major cardiovascular events and revascularization at 1 year using the 
modified Duke score compared with percent reversible defect.
AUC indicates area under the curve; CCTA, coronary computed tomographic angiography; and SPECT, 
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such as the COURAGE (Clinical Outcomes Utilizing 
Revascularization and Aggressive Drug Evaluation),6 
BARI-2D (Bypass Angioplasty Revascularization 
Investigation 2 Diabetes),7 and ORBITA (Objective 
Randomized Blinded Investigation With Optimal 
Medical Therapy of Angioplasty in Stable Angina)5 trials, 
while they did not specifically address CCTA, also sup-
port the hypothesis that patients with stable angina and 
CAD other than left main disease could be successfully 
treated by OMT alone, with mortality outcomes similar 
to those of patients who had interventions. Regarding 
the modified Duke score, as with RESCUE, Min et al 
found that the modified Duke score with CCTA provided 
prognostic information regarding MACE.19 Both meth-
ods provide a measure of the myocardium at risk.25
The results of RESCUE should be interpreted in 
the context of certain limitations. Limitations of the 
RESCUE trial include modest adherence rates to 
OMT. In RESCUE, adherence rates for OMT were 
comparable in the 2 groups at just below 39% over 
the follow-up period. This is significantly less than 
COURAGE,26 in which adherence to OMT was 80% 
at 5 years and ISCHEMIA, where adherence to OMT 
ranged from 73.9% to 81.5%, but comparable to ad-
herence rates in a real-life setting.27 In COURAGE and 
ISCHEMIA, higher OMT adherence rates were most 
likely secondary to not only the regularly scheduled 
nurse manager visits, but also the provision of medica-
tions or some medications at no cost to the patient.8,26 
In RESCUE, power was decreased by reducing the 
Figure 3. Proximal and LAD segments for CCTA were significantly better predictors for the 
composite end point of major adverse cardiovascular event and revascularization than percent 
reversible defect (Rdefect).
AUC indicates area under the curve; CCTA, coronary computed tomographic angiography; LAD, left 
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sample size from 4300 to 1050 patients, event rates 
were lower than expected suggesting mild-to-moder-
ate ischemic disease, and the period of follow-up was 
modest, at an average of 16.2 months. The power of 
the study may have also affected the results of the 
secondary aims.
The findings in RESCUE do not apply to patients 
with acute coronary syndromes, low ejection fraction, 
or heart failure. Patients with left main disease and 
continued symptomatology despite patient-described 
adherence to OMT were directed to revascularization.
In conclusion, we compared treatment paradigms 
with initial imaging with CCTA to initial imaging with 
SPECT-MPI in directing patients with stable angina to 
OMT alone or OMT with revascularization and, within 
the limitations described above, found no difference 
in patient outcomes. Findings suggest that CCTA is a 
better predictor of MACE and revascularization.
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Table S1. Demographics and CAD Risk factors 






AGE - YR MEAN 57(SD=9) 58(SD=9) 
RANGE 40-85 40-86
BMI** MEAN 30 (SD=5) 29 (SD=5) 
RANGE 16-41 17-43
RACE AMERICAN INDIAN OR ALASKA 8(2%) 7(1%) 
ASIAN 11(2%) 14(3%) 
BLACK OR AFRICAN AMERICAN 73(14%) 77(15%) 
NATIVE HAWAIIAN OR OTHER 2(<1%) 1(<1%) 
WHITE 400(78%) 415(78%) 
MULTIPLE RACE ENDORSEMENT 10(2%) 5(1%) 
UNKNOWN 12(2%) 12(2%) 
ETHNICITY HISPANIC OR LATINO 46(9%) 58(11%) 
NOT HISPANIC OR LATINO 467(91%) 468(88%) 
UNKNOWN 3(1%) 5(1%) 
SEX FEMALE 233(45%) 244(46%) 
MALE 283(55%) 287(54%) 
CCSS ANGINA** 
 
CLASS I 297(58%) 305(57%) 
CLASS II 183(35%) 181(34%) 
CLASS III 33(6%) 35(7%) 
CARDIAC RISK**+ 
 
CAD, ACS OR AMI FEMALE <65 YEARS AGE 73(14%) 74(14%) 
DIABETES MELLITUS 105(20%) 114(21%) 
DIAGNOSIS OF CAD, ACS OR AMI MALE <55 YEARS 
 
136(26%) 125(24%) 
DYSPNEA 257(50%) 258(49%) 
HAVE YOU SMOKED CIGARETTES, EVEN A PUFF, 
     
74(14%) 87(16%) 
IN THE PAST 30 DAYS 
HYPERCHOLESTEROLEMIA/HYPERLIPIDEMIA 324(63%) 313(59%) 
HYPERTENSION 318(62%) 317(60%) 
PRIOR HISTORY OF CAD 57(11%) 55(10%) 
TRIGLYCERIDEMIA 114(22%) 121(23%) 
* 3 Participants were taken off-study, and are not included in the analysis set
** 1034/1047 participants submitted data on the relevant case report form








Table S2. Reasons randomized scan not performed 
 
 Arm 
Reason CCTA SPECT Total 
Equipment 2 0 2 
Ineligible 0 1 1 
Insurance 1 7 8 
Medical 15 14 29 
Participant 22 38 60 
Scheduling 2 3 5 
Unknown 1 4 5 
Total 43 67 110 
 









Scan Negative Scan Positive Scan Total 
AMI Revasc. 
No 
Event No Event AMI No Event AMI Revasc. 
No 




0 0 43 0 0 6 1 3 341 1 24 97 516 
SPECT 
3 1 63 1 1 3 2 12 422 1 7 15 531 
Total 


















Relation to Study Procedure  
Total 
Relation to Study Procedure  
Total 
Unrelated Unlikely Possible Probable Definite Unrelated Unlikely Possible Probable Definite N 
Mild 0 1 3 0 0 4 1 0 0 0 0 1 5 
Moderate 2 0 0 0 1 3 0 2 0 0 0 2 5 
Severe 3 0 0 0 0 3 2 0 0 0 0 2 5 
Life threatening 0 0 0 0 0 0 1 0 0 0 0 1 1 
Fatal 0 0 0 0 0 0 0 0 0 0 0 0 0 








Table S5. Patient adherence to OMT 
Group Follow-up Compliant N Percent 
All Cases 6m 44 128 34.4 
All Cases 12m 45 118 38.1 
All Cases 18m 39 88 44.3 
All Cases 24m 19 47 40.4 
All Cases Total 147 381 38.6 
     
CCTA Cases 6m 39 108 36.1 
CCTA Cases 12m 37 97 38.1 
CCTA Cases 18m 31 74 41.9 
CCTA Cases 24m 16 40 40.0 
CCTA Cases Total 123 319 38.6 
     
SPECT Cases 6m 5 20 25.0 
SPECT Cases 12m 8 21 38.1 
SPECT Cases 18m 8 14 57.1 
SPECT Cases 24m 3 7 42.9 
SPECT Cases Total 24 62 38.7 
 
Table S6. CCTA Modified Duke Score 
  
 
Modified Duke prognostic score  N % 
(1)  <50% stenosis 287 71.6% 
(2) >=2 stenoses 30-49% (including 1 artery w/ proximal disease) or 1 
vessel w/ 50-69% stenosis 
44 11.0% 
(3) 2 stenoses 50-69% or 1 vessel w/ >=70% stenosis 28 7.0% 
(4) 3 stenoses 50-69% or 2 vessels w/ >=70% stenosis or proximal left 
anterior descending stenosis >=70% 
28 7.0% 
(5) 3 vessels >=70% stenoses or 2 vessels >=70% stenosis w/ proximal 
left anterior descending 
6 1.5% 
(6) Left main stenosis >=50% 8 2.0% 








Table S7. Results of univariate logistic regression models, summarizing the 
ability of individual AHA 16-arterial segments to predict composite outcome 

















LAD mid 0.86 
LAD proximal  0.76 
RCA mid  0.71 
LAD distal 0.69 
LAD diagonal 1  0.68 
LCX proximal  0.68 
RCA distal  0.63 
LAD diagonal 2 0.62 
RPDA 0.61 
RCA proximal  0.59 
LCX obtuse marginal 2  0.59 
LCX distal 0.59 
Left main 0.57 
Ramus 0.57 
LCX obtuse marginal 1  0.57 
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